338 related articles for article (PubMed ID: 14719072)
1. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
3. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
4. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
[TBL] [Abstract][Full Text] [Related]
5. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
6. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
7. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.
Matsushita S; Nitanda T; Furukawa T; Sumizawa T; Tani A; Nishimoto K; Akiba S; Miyadera K; Fukushima M; Yamada Y; Yoshida H; Kanzaki T; Akiyama S
Cancer Res; 1999 Apr; 59(8):1911-6. PubMed ID: 10213500
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
[TBL] [Abstract][Full Text] [Related]
9. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
12. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides.
Fukushima M; Suzuki N; Emura T; Yano S; Kazuno H; Tada Y; Yamada Y; Asao T
Biochem Pharmacol; 2000 May; 59(10):1227-36. PubMed ID: 10736423
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer.
Shintani M; Urano M; Takakuwa Y; Kuroda M; Kamoshida S
Oncol Rep; 2010 May; 23(5):1345-50. PubMed ID: 20372850
[TBL] [Abstract][Full Text] [Related]
14. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Lee JJ; Seraj J; Yoshida K; Mizuguchi H; Strychor S; Fiejdasz J; Faulkner T; Parise RA; Fawcett P; Pollice L; Mason S; Hague J; Croft M; Nugteren J; Tedder C; Sun W; Chu E; Beumer JH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):515-26. PubMed ID: 26787503
[TBL] [Abstract][Full Text] [Related]
15. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Tsuchiya H; Kuwata K; Nagayama S; Yamashita K; Kamiya H; Harashima H
Drug Metab Pharmacokinet; 2004 Jun; 19(3):206-15. PubMed ID: 15499188
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
Yano S; Kazuno H; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
Bioorg Med Chem; 2004 Jul; 12(13):3431-41. PubMed ID: 15186829
[TBL] [Abstract][Full Text] [Related]
19. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
[TBL] [Abstract][Full Text] [Related]
20. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]